BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for...
27 insider sale filings on record · latest filing 2026-10-09.
No open-market insider purchases (SEC Form 4 code P) on record for BNTX.